medigraphic.com
ISSN 1405-1710 (Print)

2020, Number 2-3

Next >>

Rev Cent Dermatol Pascua 2020; 29 (2-3)

Efficacy and safety of two isotretinoin treatment schemes in adults with rosacea: randomized clinical trial

Jurado-Santa CF, Torres-Victoria TR, Peralta-Pedrero ML, Garza-Zúñiga MJ, Morales-Sánchez MA

Language: Spanish
References: 17
Page: 47-55
PDF size: 329.91 Kb.


ABSTRACT

Introduction: Rosacea is an inflammatory skin disease that affects quality of life. Isotretinoin is a therapeutic alternative in severe cases. Controversy exists about the efficacy of low-dose isotretinoin for the treatment of papulo-pustular rosacea. Material and methods: Randomized clinical trial enrolling 68 patients with papulo-pustular rosacea. Participants were randomly assigned to two doses of isotretinoin, group A received 20 mg/day and group B 10 mg/day for 12 weeks. The response variables were the lesion count, the level of erythema and melanin at zero, four, eight and 12 weeks. Change in quality of life at 12 weeks and adverse effects were measured throughout the study. Recurrence was assessed at 24 weeks. Results: The reduction in the number of lesions were similar in both groups, as well as the incidence of adverse effects. The quality of life improved in both groups, as did the level of erythema. The level of melanin was lower at the end of the treatment in the group that received 20 mg/day of isotretinoin. Conclusions: The efficacy and safety of both isotretinoin dose schedules are similar, due to this results the use of isotretinoin 10 mg/day is recommended for patients with papulo-pustular rosacea.


REFERENCES

  1. Van Zuuren EJ. Rosacea. New Engl J Med. 2017;377:1754-1764. Available in: https://doi.org/10.1056/NEJMcp1506630.

  2. Van Zuuren EJ, Fedorowicz Z, Carter B, Van der Linden MM, Charland L. Interventions for rosacea. Cochrane Database Syst Rev. 2015;2015:CD003262.

  3. Powell FC. Rosacea. N Engl J Med. 2005;352:793-803.

  4. Gether L, Overgaard LK, Egeberg A, Thyssen JP. Incidence and prevalence of rosacea: a systematic review and meta-analysis. Br J Dermatol. 2018;179:282-289. Available in: https://doi.org/10.1111/bjd.16481.

  5. Culp B, Scheinfeld N. Rosacea: a review. P T. 2009;34:38-45.

  6. Amir A, Scott AD, Amy JM, Steven F. Rosacea in skin of color: not a rare diagnosis. Dermatol Online J. 2014;20(10):13030/qt1mv9r0ss.

  7. Marson JW, Baldwin HE. Rosacea: a wholistic review and update from pathogenesis to diagnosis and therapy. Int J Dermatol. 2020;59:e175-e182. Available in: https://doi.org/10.1111/ijd.14757.

  8. Gallo RL, Granstein RD, Kang S, Mannis M, Steinhoff M, Tan J et al. Standard classification and pathophysiology of rosacea: The 2017 update by the National Rosacea Society Expert Committee. J Am Acad Dermatol. 2018;78:148-155. Available in: https://doi.org/10.1016/j.jaad.2017.08.037.

  9. Zeichner JA, Eichenfield LF, Feldman SR, Kasteler JS, Ferrusi IL. Quality of life in individuals with erythematotelangiectatic and papulopustular rosacea: findings from a web-based survey. J Clin Aesthet Dermatol. 2018;11:47-52.

  10. Thiboutot D, Anderson R, Cook-Bolden F, Draelos Z, Gallo RL, Granstein RD et al. Standard management options for rosacea: the 2019 update by the National Rosacea Society Expert Committee. J Am Acad Dermatol. 2020;82:1501-1510. Available in: https://doi.org/10.1016/j.jaad.2020.01.077.

  11. Hoting E, Paul E, Plewig G. Treatment of rosacea with isotretinoin. Int J Dermatol. 1986;25:660-663. Available in: https://doi.org/10.1111/j.1365-4362.1986.tb04533.x.

  12. Rademaker M. Very low-dose isotretinoin in mild to moderate papulopustular rosacea; a retrospective review of 52 patients. Australas J Dermatol. 2018;59:26-30. Available in: Available in: https://doi.org/10.1111/ajd.12522.

  13. Sbidian E, Vicaut E, Chidiack H, Anselin E, Cribier B, Dréno B et al. A randomized-controlled trial of oral low-dose isotretinoin for difficult-to-treat papulopustular rosacea. J Invest Dermatol. 2016;136:1124-1129. Available in: https://doi.org/10.1016/j.jid.2016.01.025.

  14. Van Zuuren EJ, Ben Carter ZF, van der Linden M, Charland L. Interventions for rosacea. Cochrane Database Syst Rev. 2015;2015:CD003262.

  15. Gollnick H, Blume-Peytavi U, Szabó EL, Meyer KG, Hauptmann P, Popp G et al. Systemic isotretinoin in the treatment of rosacea –doxycycline– and placebo-controlled, randomized clinical study. J Dtsch Dermatol Ges. 2010;8:505-515. doi: 10.1111/j.1610-0387.2010.07345.x.

  16. Sbidian E, Vicaut É, Chidiack H, Anselin E, Cribier B, Dréno B, Chosidow O. A randomized-controlled trial of oral low-dose isotretinoin for difficult-to-treat papulopustular rosacea. J Invest Dermatol. 2016;136:1124-1129. doi: 10.1016/j.jid.2016.01.025.

  17. Lenz CR, Aldrich SL. Effect of systemic isotretinoin treatment on melasma : a case study and literature review. Clinical Dermatology Open Access Journal. 2019; 1-6. Available in: https://doi.org/10.23880/cdoaj-16000182.




2020     |     www.medigraphic.com